Company intelligence / Profile preview
Planet Biotechnology, Inc.
Hayward, CA, USAplanetbiotechnology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has multiple programs in discovery and preclinical stages, with a focus on infectious diseases. Their lead candidates include Fc3/SCR(19-20) for tick-borne diseases and DPP4-Fc for MERS-CoV.
- Therapeutic areas
- Infectious Diseases
- Modalities
- AntibodiesReceptor/ligand-Fc fusion proteinsRecombinant proteinsImmunoadhesins
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
DARPA (contract no. HR001113D-0004)
Beyond the preview
Go deeper on Planet Biotechnology, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Planet Biotechnology, Inc..